SCHEMBL21467079

SCHEMBL21467079

Cc1c[nH]c2ccc(-c3n[nH]c4ncnc(N)c34)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.46
KCNH2 Q12809 1/20 0.46
KDR P35968 11/20 0.43
PIK3CD O00329 11/20 0.39
PIK3CA P42336 11/20 0.39
PIK3CG P48736 11/20 0.39
PRKDC P78527 11/20 0.39
EGFR P00533 10/20 0.39
PIK3CB P42338 10/20 0.39
ABL1 P00519 9/20 0.39
HCK P08631 9/20 0.39
SRC P12931 9/20 0.39
MTOR P42345 9/20 0.39
EPHB4 P54760 9/20 0.39
PI4KB Q9UBF8 4/20 0.39
MAP3K11 Q16584 1/20 0.37
FLT1 P17948 2/20 0.36
PRKD3 O94806 2/20 0.36
AURKA O14965 1/20 0.36
DAPK3 O43293 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17970622 0.90 KDR (0.44) TGFBR1KCNH2KDRPIK3CDPIK3CA
SCHEMBL21467105 0.82 JAK2 (0.46) KDRPIK3CDPIK3CAPIK3CGPRKDC
SCHEMBL129822 0.78 PIK3CD (0.63) TGFBR1KCNH2KDRPIK3CDPIK3CA
SCHEMBL17970655 0.78 KDR (0.51) TGFBR1KDRPIK3CDPIK3CAPIK3CG
SCHEMBL3782102 0.76 PIK3CD (0.57) KDRPIK3CDPIK3CAPIK3CGPRKDC
SCHEMBL21467106 0.76 PIK3CD (0.39) TGFBR1KDRPIK3CDPIK3CAPIK3CG
SCHEMBL27753701 0.75 SRC (0.67) KDRPIK3CDPIK3CAPIK3CGPRKDC
SCHEMBL22275989 0.74 MAP4K4 (0.49) PIK3CDPIK3CAPIK3CGPRKDCPIK3CB
SCHEMBL30386858 0.74 PIK3CD (0.61) KDRPIK3CDPIK3CAPIK3CGPRKDC
SCHEMBL23917483 0.73 PIK3CD (0.60) KCNH2KDRPIK3CDPIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 TGFBR1 2783/4885KCNH2 4148/4885KDR 866/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A TGFBR1 939/4885KCNH2 3781/4885KDR 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.